Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock

2 hours ago 1

Shares of Summit Therapeutics (NASDAQ:SMMT) traded higher on Friday after Robert Duggan and Maky Zanganeh, co-CEOs of the cancer drug developer, bought nearly $12M worth of company stock.
According to SEC filings on Thursday, Duggan and Zanganeh each purchased